PF-07985045 / Pfizer - LARVOL DELTA

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov) - P1 | N=30 | Terminated | Sponsor: Pfizer | Not yet recruiting ➔ Terminated; The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.

IO biomarker • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • KRAS • ROS1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov) - P1 | N=30 | Terminated | Sponsor: Pfizer | Trial completion date: Mar 2029 ➔ May 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Mar 2028 ➔ May 2026; The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.

IO biomarker • Trial completion date • Trial primary completion date • Trial termination • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • ALK • KRAS • ROS1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=190 ➔ 26

Enrollment change • Enrollment closed • IO biomarker • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • ALK • KRAS • ROS1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene (clinicaltrials.gov) - P1 | N=190 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Colorectal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS